BioCentury | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

...Adams Street Partners, Sanofi Ventures and NanoDimension, as well as seed investors. Karen Tkach Tuzman, Associate Editor Icosavax Corp. University...
BioCentury | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

...Drachman, formerly CMO and EVP of R&D at Seattle Genetics Inc. IPD's fourth platform play, Icosavax Corp....
...Inc., Menlo Park, Calif. Harvard University, Cambridge, Mass. Howard Hughes Medical Institute, Chevy Chase, Md. Icosavax Corp....
...Wash. Targets IL-2 - Interleukin 2 Karen Tkach Tuzman, Associate Editor A-Alpha Bio Inc. Amgen Inc. Arzeda Corp. Cyrus Biotechnology Inc. Icosavax Corp. Lyell...
BioCentury | Mar 19, 2019
Distillery Therapeutics

RSV F protein-based nanoparticle vaccine for RSV infection

...of antigen-specific antibodies and neutralizing antibodies compared with the trimeric subunits alone. Next steps by Icosavax Corp....
...animal challenge models of RSV infection. TARGET/MARKER/PATHWAY: RSV F protein LICENSING STATUS: Patented; licensed to Icosavax Corp....
...Bellinzona, Switzerland email: laurent.perez@irb.usi.ch CONTACT: Neil P. King, University of Washington, Seattle, Wash. email: neilking@uw.edu Claire Quang Icosavax Corp. Institute...
Items per page:
1 - 3 of 3
BioCentury | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

...Adams Street Partners, Sanofi Ventures and NanoDimension, as well as seed investors. Karen Tkach Tuzman, Associate Editor Icosavax Corp. University...
BioCentury | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

...Drachman, formerly CMO and EVP of R&D at Seattle Genetics Inc. IPD's fourth platform play, Icosavax Corp....
...Inc., Menlo Park, Calif. Harvard University, Cambridge, Mass. Howard Hughes Medical Institute, Chevy Chase, Md. Icosavax Corp....
...Wash. Targets IL-2 - Interleukin 2 Karen Tkach Tuzman, Associate Editor A-Alpha Bio Inc. Amgen Inc. Arzeda Corp. Cyrus Biotechnology Inc. Icosavax Corp. Lyell...
BioCentury | Mar 19, 2019
Distillery Therapeutics

RSV F protein-based nanoparticle vaccine for RSV infection

...of antigen-specific antibodies and neutralizing antibodies compared with the trimeric subunits alone. Next steps by Icosavax Corp....
...animal challenge models of RSV infection. TARGET/MARKER/PATHWAY: RSV F protein LICENSING STATUS: Patented; licensed to Icosavax Corp....
...Bellinzona, Switzerland email: laurent.perez@irb.usi.ch CONTACT: Neil P. King, University of Washington, Seattle, Wash. email: neilking@uw.edu Claire Quang Icosavax Corp. Institute...
Items per page:
1 - 3 of 3